Iovance Sparks More Optimism About Lifileucel’s Commercial Potential With New Analysis

An updated Phase II analysis for Iovance Biotherapeutics, Inc.’s tumor-infiltrating lymphocyte (TIL) cell therapy lifileucel in melanoma gives a better idea of its efficacy potential and also might improve its chances for commercial success. The new look comes as the company works to complete a rolling biologics license application submission to the US Food and Drug Administration and prepares for the TIL product’s launch as one of the first approved cell therapies for a solid tumor indication.

Iovance presented pooled data from cohorts 2 and 4 in the pivotal Phase II C-144-01 trial of lifileucel in heavily pretreated melanoma patients on 10 November at the Society for the Immunotherapy of Cancer (SITC) meeting